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ABSTRACT 
 
Aim: Gradual photoreceptor/ RPE deterioration/ vision loss in AMD is common, irrespective of US 
NEI AREDS I/II supplement risk reduction, or intra-vitreal anti-VEGF pharmacology. We evaluated 
dark adaptation (DA), a broad measure of photoreceptor / RPE health, with / without                 
epigenetic modulation using a resveratrol–based caloric-restriction mimic (Longevinex 
®www.longevinex.com). 
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Study Design: Case series, bi-ocular, clinical DA evaluation in deteriorating AMD, before and after 
supplementation, under medical center compassionate use guidelines.  
Place and Duration of Study: Captain James A Lovell Federal Health Care Center, Illinois, USA, 
Optometry/Ophthalmology Departments between 4/2015 and 8/2016. 
Methods: Baseline clinical DA threshold (log DB), time (min), and fixation (%) were taken for 
patients with established atrophic AMD (n=14 eyes; 6 M / 1 F; ages 64 - 89 years), using the 
AdaptDx ® (www.maculogix.com), with pupil dilation and best refraction. Following prescription of 
Longevinex® 1 capsule qd AM, DA was repeated, with each eye’s response considered 
independent.  
Results: All but 2 eyes improved in one or more DA parameters, with 3 cases showing 
improvement by retinal macula SD OCT. Expected vs. actual (worse vs. same/better), by eye, was 
significant by Chi Square, P < .01. Additional factors affecting DA: smoking, alcohol, elevated CRP 
and statins were retrospectively evaluated. 
Conclusion: These first cases of epigenetic-induced DA stability / improvement are consistent 
with previous beneficial effects of Longevinex® such as enhanced choriocapillaris circulation. DA 
is the earliest functional AMD sign and a prime candidate for “AMD prevention”. This work merits 
expansion to controlled studies. 
 
 
Keywords: AMD; dark adaptation; epigenetics; Longevinex®; resveratrol. 
 
1. INTRODUCTION 
 
Dark adaptation (DA), as opposed to visual 
acuity, is a superior test for the presence and 
staging of AMD [1]. A MacuLogix AdaptDx® DA 
test result in excess of 6.5 minutes predicts 
future macular degeneration by at least 3 years 
before visual decline [2]. Furthermore, this 
clinical test, analogous to a glaucoma visual field, 
has a sensitivity and specificity of 90%, on par 
with the clinical performance of a retinal 
specialist [2]. Many articles provide evidence that 
resveratrol's biological activities include 
vasorelaxant activity, antiangiogenesis activity, 
anti-inflammatory activity, antioxidant activity, 
and so on through different molecular 
mechanisms using animal models and in vitro 
retinal cells. In this report, we evaluate DA using 
a resveratrol-based supplement. 
 
Short and long term improvement in visual 
function and structure has previously been 
reported in AMD patients taking Longevinex® 
capsules (Resveratrol Partners, Las Vegas, NV 
USA), a nutraceutical supplement containing red 
wine solids (including 100 mg of stabilized 
laboratory grade microionized/microencapsulated 
low-dose trans-resveratrol), metal binding 
polyphenol red wine solids, vitamin D3 1200 IU, 
DNA repair nucleotides and a B cyclodextrin 
solubilizing agent. Longevinex ® has also been 
shown to increase the thickness of the 
choriocapillaris in normal and AMD patients [3,4]. 
B cyclodextrin have been shown to lower 
cholesterol/dissolve drusen by direct injection 
and bind, stabilize and remove lipofuscin 
bisretinoids from the retinal pigment epithelium 
[5]. 
The molecular mechanism of action of 
Longevinex ® is multi-modal involving reduction 
in hypoxia inducible factor (HIF) thru down-
regulation of micro RNA 20b in turn controlling 
VEGF; 2) sequestration of labile iron and copper; 
3) enhancement of the immune response  by 
microglia and sensitization by vitamin D3 and 4) 
modulation of chemokine receptors. The 
mechanisms of actions and documentation of 
both short and long term clinical treatment, stem 
cell regeneration in ‘treatment resistant’ AMD, is 
found in a recent book chapter, Advances in 
Ophthalmology and Optometry, Beyond AREDS 
2 [6]. 
 
Our basic clinical goal is stabilization and 
improvement of function and structure of AMD 
eyes (photoreceptor / RPE function), where no 
currently available treatment exists, under 
medical center compassionate care guidelines. 
Gradual deterioration of photoreceptor / RPE 
health in untreated and treated AMD patients is 
common, irrespective of risk reduction (AREDS I, 
II supplements) or current intra-vitreal anti-VEGF 
pharmacologic approaches. The first 7 
consecutive clinical cases evaluating dark 
adaptation (DA), representative of photoreceptor 
/ RPE health, are presented. 
 
2. MATERIALS AND METHODS 
 
2.1 AdaptDx® Protocol 
 
The AdaptDx ® (MacuLogix, Middletown, PA, 
USA), with best refractive correction protocol was 
followed under scotopic conditions, based upon 
the manufacturers procedures and training 
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program. Briefly, photoreceptor / RPE (retinal 
pigment epithelium) mediated DA was measured 
psychophysically following photo-bleach. While 
viewing a red fixation LED and eye patch, the 
patient responds by a button press when 
detecting a 2-degree, 500-nm stimulus centered 
5 degrees below the point of fixation in the 
vertical meridian. The stimulus is presented 
every 2s to 3s for duration of 200 msec. A 3-
down, 1-up modified staircase threshold 
algorithm is used to determine threshold. After 
each threshold, the patient is provided a 15 
second rest break. Threshold measurements 
repeat until the patient has recovered their 
threshold to 5x10-3 scotopic cd/m2.  Clinical DA 
was performed in all cases following pupil dilation 
using tropicamide 1% and phenylephrine 
hydrochloride 2.5% instilled no less than 15 min 
before the examinations. The fellow eye was 
occluded with an eye patch.  
 
The 2 standardized AdaptDx® protocols used 
were ‘screening (maximum 6.5-minute duration)’ 
and AMD staging (maximum 20-minute duration), 
depending upon clinical presentation.  The early, 
linear part of the rod-mediated dark adaptation 
curve extracts the time required to reach a 
sensitivity of 5.0 × 10(-3) cd/m2 (time to rod 
intercept) and the slope (rod adaptation rate). [2] 
The speed of DA was characterized by this rod-
intercept value, with abnormal DA defined as 
rod-intercept of 6.5 minutes in the Rapid and 
Extend Protocols. [2] Baseline clinical DA 
threshold (log DB) at time=0, intercept time 
(min), and fixation quality (%) were taken for 7 
consecutive AMD patients with established, 
progressive, atrophic AMD (n=14 eyes; 6 M / 1 F; 
ages 64 - 89 years). All were veterans at the 
James A Lovell Federal Health Care Center 
Optometry and Ophthalmology departments, 
examined between April 2015 and August 2016.   
 
2.2 Consent /IRB and Safety/ Inclusion & 
Exclusion criteria 
 
The use of a marketed product as part of medical 
practice for an individual patient does not require 
the submission of an IND (Investigational New 
Drug). However, oversight was requested and 
approved by the Chief of Staff and IRB (Hines 
DVA, Chicago, IL). The "medication" 
Longevinex® (Longevinex Partners, Las Vegas, 
NV) has exhibited excellent safety and freedom 
from side effect at the recommended dosage (1 
capsule per day) among non-anemic subjects 
over 12 years (http://www.longevinex.com), with 
no reported hospitalizations during this extended 
time period.  Animal and human toxicity data, 
unusual for a dietary supplement, as well as fast 
track FDA petition has been submitted, and can 
be viewed on line [7]. 
 
Inclusion 1) Diagnosis of AMD; 2) Potential 
clinical benefit in consultation with a retinal 
specialist (LU) in patients without conventional 
clinical options. 
 
Exclusion 1) Anemia based on severe low RBC 
count / low hemoglobin as determined by 
medical record review (SR); 2) Inability to 
perform the DA examination. 
 
Notations were made in the chart regarding the 
patients' willingness to take a nutraceutical 
supplement pill every morning, as there were no 
additional clinical options according to retinal 
specialist consultation. Patients purchased 
Longevinex® on their own, except in the case of 
financial hardship, in which case it was provided 
by Longevinex® Partners.  
 
2.3 Prescription and DA measurements 
 
Based upon clinical recommendation, case by 
case (SR, LU); prescription of a single, capsule 
qd po AM apart from medications was prescribed 
in the presence of an abnormal DA of 6.5 
minutes or longer. DA was repeated at varying 
clinical intervals. As these were clinical patients, 
and not research subjects, no attempt was made 
to standardize DA intervals or monitor / ascertain 
supplement use compliance between 
measurements. 
 
2.4 Retrospective Medical Chart Review  
 
For the purposes of this report, we acquired (post 
hoc) demographic data of several health and 
functional characteristics that the literature has 
suggested increase AMD risk and / or alter DA 
(e.g., BMI, smoking, alcohol use, family history, 
and chronic medical conditions) [8]. We acquired 
available “retrospective data”, as abnormal DA 
has been associated with increased odds of 
elevated C-reactive protein (CRP), heavy use of 
or abstention from alcohol, high blood pressure, 
and drop in visual acuity under mesopic 
conditions. Statin medication use has also 
recently been shown to reduce drusen possibly 
improving dark adaptation [9]. 
 
2.5 Statistics 
 
A positive result is considered to be a DA curve 
that remains the same or improved over time, in 
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one or more of the 3 DA parameters (baseline 
threshold, rod intercept and fixation accuracy).  
SDOCT (spectral domain ocular coherence 
tomography) macula images were taken with a 
Zeiss 4000 instrument (Carl Zeiss Meditec, 
Dublin, CA). Chi Square statistics were applied to 
this clinical sample post hoc using Microsoft 
Excel® Statistical Software, version 14.3.1. 
Independence between eyes was assumed. 
Owing to the limited clinical data set, and the 
preliminary nature of this report, we report only 
the DA (worse vs. same/better) Chi Square, P 
<0.05 considered significant. We assume 
independence by eye with any stability or 
improvement in rod intercept, baseline sensitivity 
and fixation accuracy to be consistent with a 
positive effect of the nutraceutical. 
 
3. RESULTS  
 
3.1 Demographics 
 
DA data was available for the first 7 patients 
reported herein. Demographic post-hoc clinical 
review data (Table 1) represents the 
demographic data including age, gender, AMD 
diagnosis (years), current smoking (ppd), current 
alcohol (ounces per day), retinal dystrophy 
presence and pertinent medications and 
supplements. There were no current smokers or 
binge drinkers during the clinical measurement 
period. Five patients taking statins: case 1, 4 on 
simvastatin, case 2 on lovastatin and case 3, 5 
on atorvastatin. 
 
3.2 Dark Adaptation Parameter Changes 
 
3.2.1 Summary of clinical dark adaptation 
data  
 
(Table 2) shows DA data regarding DA reduction 
in minutes and fixation error rate at varying 
clinical intervals. Out of 14 eyes, 8 stayed the 
same/improved, 4 worsened, and 2 were 
unavailable. 
 
3.2.2 Clinical dark adaptation clinical data 
continued  
 
(Table 3) shows DA data regarding duration, log 
intercept, and baseline log sensitivity at varying 
clinical intervals and demonstrates overall DA 
improvement. Rod intercepts show improvement/ 
stability in 9/14 eyes, worsening in 4/14 eyes and 
unavailable in 1/14. Baseline log sensitivity 
showed 11/14 eyes improved/ stabilized and 
3/14 worsened. All but 2 eyes improved in one or 
more of the DA parameters across Table 2 and 
Table 3. Expected vs. actual (worse vs. 
same/better) Chi Square statistics shows a P 
value of P< 0.01, considered significant.  With 
such a small sample size, it would be beneficial 
to repeat the study on a larger scale to 
strengthen statistical power. This pilot data 
provides further support for the clinical utility of 
Longevinex® in patients afflicted with atrophic 
AMD. 
 
3.3 Dark Adaptation Graphs 
 
Figs. 1-7 show the changes in DA of all patients 
by comparing the graphs before and after a given 
length of time on Longevinex® supplementation. 
All but 2 eyes improved in one more of the DA 
parameters. Cases 1, 4, and 6 show a stark 
improvement in SD OCT. 
 
3.4 Demographic Post - Hoc Clinical 
Review 
 
Table 1 shows demographic data obtained by 
medical chart post - hoc review. This included  
age, gender, smoking / alcohol use and presence 
of a retinal or corneal dystrophy. Potential DA 
improving medication and supplements were 
also tabulated.  
 
Patients averaged 64-88 years of age, and 6 of 7 
were male. There were no current smokers or 
alcohol users that could adversely affect the DA 
response. One patient had a peripheral retinal 
‘paving stone’ dystrophy and another had a 
‘pellucid’ type peripheral corneal dystrophy. 
some 5/7 patients used a statin and 6/7 patients 
were taking pabulum type supplementation. 
 
3.5 Summary of Clinical Dark Adaptation 
Data 
 
Table 2 shows the reduction in DA in minutes for 
n=14 eyes. n = 8 eyes had the same or improved 
DA, n= 4 eyes worsened with data from 2 eyes 
unavailable. The latter unavailable data was due 
to a mismatch between short and long DA 
versions, based on an error in the original 
physician order. For fixation quality, for n=14 
eyes, most (n= 8 eyes) remained the same or 
improved by +/- 3%, and n = 6 eyes worsened.   
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3.6 Clinical Dark Adaptation Clinical Data 
Continued 
 
Table 3 summarizes the number of eyes 
improved or remaining stable in at least one of 
the three DA parameters.  For the 12 /14 eyes 
with available rod intercepts, n = 9/14 were the 
same or improved and n = 4/14 worsened with 1 
unavailable. For baseline log sensitivity (+/- 0.2 
log units), 11/14 were the same or improved, and 
only 3/14 worsened. 
 
4. DISCUSSION 
 
Macular degeneration affects millions of senior 
adults. There is no proven remedy for the early 
stages of this insidious sight-robbing eye 
disease. This is the first report of an oral 
supplement that stabilizes / improves DA function 
(and hence retinal health) in primarily advanced 
cases using an FDA approved dark adaptation 
clinical instrument. In 5 of 7 cases the response 
was bilateral and occurred in as little as 1 month 
as in case 5. Three patients also exhibited 
improvement in their macula SD OCT 
pathophysiology (cases 1, 4, 6). Finally, in 4 of 7 
patients there were profound multi-line 
improvements in their visual acuity (case 1 – 
both eyes improved, cases 3, 4, 5 - one eye 
improved). 
 
Retrospective review suggests that none of our 
patients were current smokers or binge 
alcoholics between DA time point assessments.  
These 2 factors are known to decrease DA [8]. 
The majority (5 of 7) patients were taking a statin 
before, during and after the Longevinex® Rx 
time period, obviating this as a theoretical factor 
for the DA stabilization / improvement                 
observed. Thus, our clinical observations appear 
robust. 
 
As this is a clinical observational case series, the 
range of follow-up of individual AMD patients 
varied between 1 and 7 months depending upon 
individual circumstances, and the doctor’s prior 
experience with Longevinex® efficacy. Some 
patients were taking other supplements that did 
not change during the intervention. No patient 
had other ophthalmologic treatment options. 
Notably, almost all patients (except case 2, age 
64) were 80 years of age and older, similar to the 
aged veteran demographics in our previous 
Longevinex® publications [7]. 
 
The improvement in DA reported herein is 
consistent with the staging down (improvement) 
of AMD in several eyes, consistent with the 
Adapt Dx® literature. Dark adaptation is an 
energy-requiring process, as the outer retina is 
nourished by the profusely perfused choroid [10, 
11]. This report is the first to find improved 
fixation accuracy as a 3rd AdaptDx® DA outcome 
measure in patients afflicted by AMD and is 
consistent with the improved structural changes 
noted on retinal imaging, and the improved visual 
acuity in 4 of 7 patients. 
 
A provocative recent study noted resolution of 
drusen in 45% of n=23 patients placed on 80 mg 
Lipitor ® [9]. As well, Australian pulsed laser 
studies aimed at thinning Bruch’s membrane, 
may potentially improve DA [12]. Whether the 
issue is cholesterol deposition between Bruch’s 
membrane and the RPE or a thickening of 
Bruch’s membrane, the putative mechanism for 
failing DA and worsened RPE health, in both 
cases, is believed to be translocation impairment 
of the essential vitamin A derivative “11-cis RAL” 
used in the “retinal cycle”. Retrospective chart 
review– revealed no discontinuation or 
substitution, or change in  statin dose during the 
DA time intervals during which Longevinex® was 
prescribed.   
 
The expanding ophthalmologic use of statins 
against AMD appears to be a misdirection, as 
Cochrane meta- evaluation from currently 
available RCTs are “insufficient to conclude that 
statins have a role in preventing or delaying AMD 
onset or progression” [13]. Some statins, in some 
individuals, are also fraught with side effects [14]. 
Regardless, these findings support Mullins et al.  
that micro vascular changes are related to the 
pathogenesis of AMD and vascular endothelial 
cell loss occurs in association with sub-RPE 
deposit (including cholesterol) formation [10]. 
Whether micro vascular events are a cause or 
consequence of drusen or other deposit 
formation remains to be determined.  
 
A recent cross sectional observation study 
involving 42 young healthy subjects mean age 
25±2.0 years (29% men) evaluating choroidal 
thickness, found no detectable effect on rod-
mediated DA, adjusted for age and gender [12]. 
Thus perhaps DA screening should begin with 
patients no younger than “baby boomers”. 
Notably, MacuClear® 1% hydralazine eye drops 
are thought to work by increasing choroidal blood 
flow in early to intermediate AMD with the 
electroretinogram (ERGc) wave as a biomarker.  
Phase 2/3 results are pending, and it would be 
informative to evaluate MacuClear® and DA [15]. 
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Table 1. Demographic post-hoc clinical review 
 
Case (Figure # & 
initials) 
Age Gender AMD duration Current 
smoker 
Current 
alcohol  
Retinal /Corneal 
dystrophy? (yes / no) 
DA improving 
medication? 
Supplements 
1 (NS) 86 M 2 years  N  N N 40 mg  
simvastatin 
1000IU Vit D3 
Centrum Silver QD 
1000 mg Fish oil BID 
420 mg Mg Oxide  
2 (RS) 64 F 5 years + N N Retinal 
Pavingstone 
20 mg lovastatin Centrum® 
3 (HJ) 82 M 8 years N N N 40mg atorvastatin  
4 (HJ) 89 M 9 years+ N N N 20 mg simvastatin  MaxiVision® AREDS 2, Krill Oil 
5 (CJ) 86 F 1 year N N Corneal Pellucid  20 mg atorvastatin Bright Eyes® 
6 (KW) 88 M 1 year N N N/A N/A 1000 IU Vit D  
AREDS2 
500 mg Vit C, 
1000 mg Fish oil 
7 (DR) 84 M New  N N N/A N/A Vitamin D3  
Age, gender, smoking, alcohol, retinal/corneal dystrophy presence, DA improving medication and supplements were tabulated. Ages 64-88 years, 6/7 male, no smokers or 
alcohol use. 2 patients have a retinal (pavingstone) and a corneal (pellucid) dystrophy, 5/7 statin use. 6/7 patients were taking a pabulum type supplement. 
 
Table 2. Summary of clinical dark adaptation data 
 
Case (Figure # & initials) Reduction in minutes, % (OD) Reduction in minutes, % (OS) Fixation errors (OD) Fixation errors (OS) 
1 (SN) (8, 53%) (-3, NA%) 11%33% 0%59% 
2 (SR) (-3, NA%) (-2, NA%) 9%  46% 25%28% 
3 (JH) (0, 0%)  (0, 0%)  0%  11% 11%12% 
4 (JH) (0,0%)  (0, 0%) 7%  6% 31%26% 
5 (JC) NA extended vs rapid, NA% NA extended vs rapid, NA% 28%0% 13%0% 
6 (KW) (-8, NA%) (0,0%) 29%42% 14%11% 
7 (RD) (0,0%) (0,0%) 3%18% 27%20% 
Reduction in DA in Minutes (n=14 eyes, n = 8 same / improved and n= 4 worse, 2 unavailable.  Fixation Errors (n=14 eyes, n= 8 same / improved +/- 3% and n =6 worsened).  
NA = non-applicable 
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Table 3. Clinical dark adaptation clinical data continued 
 
Case (Figure # 
& Initials) 
Duration prescribed 
longevinex® 
Rod intercept 
(OD) 
Rod intercept 
(OS) 
Baseline log 
sensitivity (OD)  
Baseline log 
sensitivity (OS) 
#Eyes improved 
OR remained stable in at 
least 1 DA factor 
1 (SN) 5 Weeks 17.399.34 2.57 6.10 ~1.9~2.2 2.82.1 1 ( L eye parameters worse) 
2 (SR) 7 Months 5.738.84 2.043.90 ~1.3~1.2 ~2.1~2.3 2 (L eye remains normal)  
3 (JH) 4.5 Months >6.5>6.5 >6.5N/A (Cannot  
be calculated) 
~1.8~2.3 ~2.2~2.6 2 
4 (JH) 4 Months >20>20 >20>20 ~1.1~1.4 ~1.2~1.6 2 
5(JC) 1 Month >20>6.5 >20>6.5 1.2>1.2 1.01.1 2 
6 (KW) 4 Months 11.919.85 >20>20 ~1.51.0 ~0.9~1.2 1 (R eye parameters worse) 
7 (RD) ~4 Months >20>20 >20>20 ~1.1~0.9 ~1.0~1.1 2 
#Eyes improved or remained stable in at least 1 DA factor.( 12 /14) Rod Intercept data (n = 9/14 same/ improved; n = 4/14 worse, 1 unavailable.  Baseline Log Sensitivity +/- 0. 
2 (11/14 = same / improved, 3/14 = worsened)
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Fig. 1a, b. Longevinex ® x 5 weeks 
Patent SN, an 86 y/o Caucasian male with atrophic AMD for 2 years w vascular component and abnormal R DA, was prescribed Longevinex®.  Medical records note glaucoma 
suspicion R optic nerve vs optic neuropathy. Fig. 1a DA shortened from ~17 to 8 min R retina, with improvement in baseline log (db) sensitivity but not fixation and 3 line 
improved VA from 20/50 to 20/25.  (His L retina DA was normal at baseline and follow-up (below 6.5 minutes), with 2 line improved VA from 20/40 to 20/25. (not shown) Fig. 1b 
shows significant improved registered macula SDOCT thickness DIFFERENCE at follow-up, with an increase in retinal thickness of 20 µm in the superior parafovea EDTRS 
quadrant, well beyond the 5u instrument axial resolution.  This is the most vulnerable area of the retina in early AMD, and the location of the MacuLogix Adapt Dx® target 
stimulus 
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Fig. #2a, b. Longevinex® x 7 months 
Patient SR, a 64 y/o Caucasian female with atrophic AMD for 5 years, was prescribed Longevinex (R) for 7 mo.  Fig. 2a: DA lengthened from ~6 min to ~9min R retina but with 
significantly decreased fixation from 46 % to 9 %, and decreased baseline sensitivity.  Fig. 2b: Normal DA, increasing slightly from ~ 2.75 min to 3.5 min. VA stayed the same 
at 20/30 each retina 
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Fig. #3a, b. Longevinex® x 4.5 months 
Patient JH, an 82 y/o Caucasian male with severe atrophic AMD for 8 years was prescribed Longevinex® and followed for 4.5 mo. Bilateral DA improvement in baseline 
sensitivity, without significant change in or DA (min) or fixation in standard clinical testing mode (actually worse R eye). VA R retina improved from 20/40 to 20/25 (3 lines). 
Unfortunately, 20 minute extended AMD DA staging exam was not ordered.  This patient noted that his R eye has improved, and his L eye showed no signs of further visual 
deterioration. 
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Fig. #4a, b, c. Longevinex® x4 months  
A second patient JH, an 88 y/o Caucasian male with atrophic AMD for at least 9 years , showing improvement L eye > R  eye  in extended time – frame  DA,  after 1 month of 
prescribed  Longevinex ®.  Retinal sensitivity improved as clearly evident in his L eye beginning at 6 min. The L retina DA slope is steeper with ending sensitivity ~ 1 log unit 
more sensitive (lower curve).  VA R improved from 20/60 to 20/40 (2 Snellen lines).  VA stayed the same in his left eye. Fig. C. There was a significant 19u increase in L 
SDOCT retinal foveal thickness of 19µm, and 7u superior parafovea L retina explaining better fixation and improved DA log sensitivity 
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Fig. #5a, b. Longevinex® x 1 month 
Patient JC, an 86 y/o Caucasian male, with atrophic AMD for 2 years, prescribed Longevinex ® for ~ 6 wks. Fig. 5a: No improvement in DA sensitivity or slope, but dramatically 
improved fixation with a 2 line improvement in VA R eye (20/30 to 20/20) Fig. 5b: Improvement in L retinal sensitivity and fixation is evident 
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Fig. #6a, b, c, d. Longevinex® x 4 months 
Patient KW, 88 y/o male, with atrophic AMD for 1 year and prescribed Longevinex® for 4 mo. Fig. 6a Worsened DA R retina by all 3 DA attributes. Fig. 6b Improved L retina 
baseline and extended retinal sensitivity and fixation.  VA was approximately the same at 20/60 R and 20/40 L. Fig. 6c, d Patient KW shows significant increase in his retinal 
thickness R retina by 30µm in the center and in his L retina by 7µm in the center 
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Fig. 7a, b. Longevinex ® x ~4 months 
Patient RD, an 84 y/o Caucasian male with newly diagnosed advanced atrophic AMD prescribed Longevinex ® for ~4 month stable DA and no loss of retinal function, despite 
an additional 4 months of aging. VA improved 3 lines from 20/40 to 20/25 R eye and L eye remained the same at 20/25. 
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Compared with statins, Longevinex® has several 
key advantages with lack of side effects, after 12 
years in the marketplace.  The benefits to the 
vascular system extend beyond resveratrol and 
include: 
 
• Decreased inflammation (COX-2, CRP) 
• Decreased HIF-1 and VEGF gene 
expression (miRNA 21, 20b, 539) 
• Increased expression of Nrf2 mediated 
endogenous antioxidants (GSH) 
• Decreased blood clotting (platelet 
adhesiveness) 
• Increased vasodilation (the nitric oxide 
beneficial effect on the choriocapillaris) 
• Increased divalent metal chelation (against 
labile oxidant Fe++, Cu++) 
• Decreased oxidation and peroxidation 
• Decreased cell adhesion (of platelets, 
microbes and  tumors) 
• Decreased calcification (i.e., of arterioles 
and Bruch membrane) [5] 
 
Longevinex® not only decreases cholesterol, but 
has been shown to restore myocardial 
dysfunction in hyper-cholesterolemic animals. 
[16] In addition, it manifests:  
 
1) No cytotoxicity at high dose (no hormesis), 
whereas resveratrol at high dose has toxicity; 
2) Is beneficial against human metabolic 
syndrome [17,6]; 3) Functions as an anti-
diabetic drug with insulin like sugar level 
reducing effects and 4) Promotes choroidal 
vasorelaxation and thickening [4,5]. 
  
The patients in our study were 80 years of age, 
or older. The literature is consistent with the 
conjecture that DA extension to children of AMD 
patients is desirable. These patients, who have 
not lost measurable vision, may nonetheless 
benefit from “AMD detection combined with 
epigenetic prevention” via small molecular weight 
nutrient intake [6]. To wit, some 22 -23% of naïve 
subjects have impaired dark adaptation and 
hence impaired photoreceptor / RPE health [8, 
18]. According to Owsley et al, these patients are 
more likely to have elevated CRP (c reactive 
protein), smoke, use alcohol, have hypertension 
and have poor mesopic and low luminance vision 
[7]. 
 
There are ~48 million Americans over the age of 
65 and if the above figures translate to the entire 
population (22% of ~50 million), dark adaptation 
testing could uncover ~11 million senior 
Americans with near-perfect visual acuity who 
will develop macular degeneration in their near 
future. This is exactly the time to intervene, or in 
theory, prevent AMD. 
 
The greater application of this dark adaptation 
vision test is also among younger family 
members of individuals who have been 
diagnosed with macular degeneration since 
prolonged dark adaptation time can predict future 
onset of this dreaded eye disease up to 4 years 
before it can be clinically diagnosed. Forty-five 
percent (45%) of the population who have a 
parent with macular degeneration will develop 
the disease in their lifetimes. 
 
5. CONCLUSIONS 
 
Prolonged dark adaptation time is a marker of 
the future onset of a dreaded vision problem - 
macular degeneration. Subclinical AMD is a 
highly prevalent disease that in theory causes 
avoidable vision loss years before an eye doctor 
can see visible changes within the retina.  DA is 
the new biomarker for AMD detection for both 
diagnosis and staging. Prevention and not mere 
detection is the ultimate public health goal. 
Combining MacuLogix AdaptDx ® screening with 
resveratrol based therapies such as Longevinex 
® supplementation may alter the natural time 
course of AMD. Our observations should be 
validated in a controlled manner as it is an 
efficient and cost effective strategy for large 
populations of at risk patients. Moreover, proven 
medical, laser or surgical treatment for the 
common early form of macular degeneration is 
lacking. 
 
PATIENT CONSENT 
 
Informed consent was noted in the medical chart 
based upon the patient / doctor consent process 
for compassionate use of Longevinex® at the 
James A Lovell FHCC, per medical center 
guidelines. 
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